Evidence map›Paper›PMID 41049090›Full record

ArticleMolecular therapy. Nucleic acids2025

mRNA vaccine based on high-frequency prevalent antigens provides broad protection against influenza B virus.

Ziqi Cheng, Yeqing Sun, Yunbo Bai, Xi Wu, Ziqi Sun, Qingfeng Zhang, Weijin Huang, Junfeng Ma, Chenyan Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ziqi ChengNational Engineering Laboratory for AIDS Vaccines, School of Life Sciences, Jilin University, Changchun, China.
Yeqing SunNational Engineering Laboratory for AIDS Vaccines, School of Life Sciences, Jilin University, Changchun, China.
Yunbo BaiDivision of HIV/AIDS and Sexually-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing 102629, China.
Xi WuDivision of HIV/AIDS and Sexually-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing 102629, China.
Ziqi SunDivision of HIV/AIDS and Sexually-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing 102629, China.
Qingfeng ZhangDivision of HIV/AIDS and Sexually-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing 102629, China.
Weijin HuangDivision of HIV/AIDS and Sexually-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing 102629, China.
Junfeng MaNational Engineering Laboratory for AIDS Vaccines, School of Life Sciences, Jilin University, Changchun, China.
Chenyan ZhaoDivision of HIV/AIDS and Sexually-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing 102629, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza B virus (IBV) is a major pathogen affecting the human respiratory tract. B/Victoria is currently the only prevalent influenza B lineage as B/Yamagata has become increasingly rare. Existing influenza vaccines provide limited protection because of the continuous antigenic drift within hemagglutinin (HA), a key membrane protein within the virion. Therefore, the development of novel pan-IBV vaccines has become an urgent priority. In this study, we formulated a high-frequency prevalent antigen (HFPA)-mRNA vaccine based on 10-year prevalent sequences of HA, neuraminidase, nucleoprotein, and the HA stem. We then assessed the broad-spectrum protective effects of the prevalent antigens. The HFPA vaccine induced more robust humoral immune responses, including higher titers of broad-spectrum neutralizing and neuraminidase-inhibiting antibodies and enhanced antibody-dependent cell-mediated cytotoxicity, than attenuated IBV vaccines. The HFPA vaccine also induced a Th1-biased CD4

Indexed as

broad protectionIBVMT: Oligonucleotides: Therapies and Applicationspan-IBV vaccineprevalent antigen

Identifiers

PMID41049090
PMCPMC12493149

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.